Survival of the Fittest vs. Solution. Antibiotic Stewardship or Reinventing the Wheel
|
|
- Audra Imogene Peters
- 6 years ago
- Views:
Transcription
1 Antibiotic Stewardship or Reinventing the Wheel Ellie JC Goldstein MD Director, R M Alden Research Laboratory Clinical Professor of Medicine, UCLA Survival of the Fittest vs. Solution Darwin 1984
2 The Evolution of Cooperation When should a person co-operate and when should a person be selfish? should a friend keep providing favors to another friend who never reciprocates?... Under what conditions will co-operation emerge in a world of egoists? Success in an evolutionary "game correlated with Be nice: cooperate, never be the first to defect. Be provocable: return defection for defection, cooperation for cooperation. Don't be envious: be fair with your partner. Don't be too clever: or, don't try to be tricky. Resistant Organisms 2011: When One is Targeted, What is the Effect on the Non-Targets? Current Issues MRSA Vancomycin MIC creep VRE ESBL Increasing prevalence P. aeruginosa Pan-resistance Acinetobacter Pan-resistance E. coli (NDM1) Integrons K. pneumoniae carbapenemase (KPC) Future? What Next?
3 Impact of Antibacterial Resistance 100,000 people 1. Klevens RM, et al. Public Health Rep. 2007;122: Stone PW, et al. Am J Infect Control. 2005;33: ~1.7 million patients in US hospitals acquire an infection resulting in 100,000 deaths ANNUALLY 1 This results in an additional $6.5 billion in health care expenditures 2 On October 1, 2008, CMS limited reimbursement for hospital-acquired acquired conditions deemed preventable Catheter-associated associated urinary tract infections Vascular catheter-associated associated infections Mediastinitis after coronary artery bypass graft surgery Surgical site infections D Goff DEALING WITH ANTIBIOTIC RESISTANCE & NEW DRUG DEVELOPMENT ENTITY WHO WHAT White House President Obama TransAtlantic TF on Abx Resist. TATFAR Congress House (6331) Generating Abx Incentives(GAIN) Senate (2313) STARR PAMITA FDA M. Hamberg, et al Agency priority NIH T. Fauci Clinical Trials Network HHS Sebelius Public Health Emergencies CDC Srinivasan Surveillance; Get Smart Media Extensive Societies 21 Endorsed (J Bartlett 2011)
4 Microbiology ID Physician Epidemiology Why Have Antimicrobial Stewardship? ASP ID Pharmacist Information Services Infection Control Antibiotics are unlike any other drugs Anyone can prescribe antibiotics despite a lack of specialized training Antimicrobials benefit the prescribed patient but can impact countless others Resistant microorganisms can be spread to patients who have never received an antibiotic D Goff CA Senate Bill No. 739 Approved by Governor September 28, (a) By January 1, 2008, the department shall take all of the following actions to protect against health care associated infections (HAI) in general acute care hospitals statewide: (4) Require that general acute care hospitals develop a process for evaluating the judicious use of antibiotics, the results of which shall be monitored jointly by appropriate representatives and committees involved in quality improvement activities. 8
5 CA SB 739: What Does this Mean? By January 1, 2008 each CA acute care hospital: Monitor and evaluate antimicrobial use Assemble a quality improvement committee to oversee antimicrobial use Each hospital left to comply on its own CDPH HAI Program interpretation: each CA acute care hospital should have an ASP Meeting February 17, 2011 Formal education course for ASP physician and pharmacist 9 Healthcare Associated Infections Advisory Committee Meeting February 17, 2011 ASP should monitor process and outcome measures: Risk assessment including scope of practice Usage patterns for broad-spectrum antimicrobials Defined Daily Dose (DDD) or Days of Therapy (DOT) Examined for appropriateness Multidrug-resistant organism trends Medical Use Evaluations Antibiogram prepared according to CLSI standards and distributed to clinical staff 10
6 Antimicrobial Stewardship Team Stakeholder Involvement: Ideal versus Reality Clinical Pharmacist ID Physician Clinical Pharmacist Infection Control Professional Patient Clinical Microbiologist Patient ID Physician Hospital Epidemiologist Information System Specialist Each Member needs a defined role Optimal Team Members (A-III) 1 Core Team Members (A-III) 1 1. Dellit TH, et al. Clin Infect Dis. 2007;44: Drew RH. J Manag Care Pharm. 2009;15:S D Goff Appropriate Antimicrobial Therapy Matches antibiotic sensitivities of the organism to the antibiotic used Improved Outcomes = Reductions In: Hospital and infection-related mortality Infection-related morbidity Length of hospital stay Days of antimicrobial therapy Cost of hospitalization 1. Pelz RK, et al. Intensive Care Med ;28: Engemann JJ, et al. Clin Infect Dis ;36: Kollef M, et al. Chest ;115: Lodise TP, et al. Clin Infect Dis ;34: Song X, et al.. Infect Control Hosp Epidemiol ;24: Toubes E, et al. Clin Infect Dis. 2003;
7 Antibiotics as Percentage of Total Healthcare Costs CAP 1 HAP 2 Abdominal trauma 3 Diabetic foot 4 Burn Total Costs (%) Antibiotic cost Healthcare cost 1. Dresser LD, et al. Chest. 2001;119: McKinnon PS, et al. Clin Infect Dis. 1997;24: Paladino JA & Fell RE. Ann Pharmacother. 1994;28: Nicolau DP, et al. J Burn Care Rehabil. 1994;15: Friedrich LV, et al. Am J Hosp Pharm. 1992;49: Balancing Effective Therapy With Concerns About Resistance Dilemma: Use broad-spectrum agents or regimens sparingly, yet promptly When does the need to treat outweigh waiting for culture results? Critically ill, febrile patients Prior antibiotic use Prolonged mechanical ventilation / recent surgery Prolonged hospital stay; healthcare associated inf. Weber DJ. Int J Infect Dis. 2006;10:S17-24.
8 Hospital and Societal Costs of Antimicrobial-Resistant Infections Projected cost savings if antimicrobial-resistant resistant infection (ARI) rates were reduced from 13.5% to 10.0% Current ARI rate: 13.5% Reduced ARI rate: 10.0% Cost $12,000,000 $10,688,004 $10,000,000 $8,000,000 $7,978,299 } $6,000,000 $4,000,000 $3,494,544 $2,583,732 $2,000,000 $0 13.5% ARI proportion 10.0% Medical Cost Roberts RR, et al. Clin Infect Dis ;49: Societal Cost Savings for 1391 patients: $2.7 million total $1,948 per patient Inappropriate Therapy Often Due to Antibiotic Resistance Inappropriate therapy more likely if antibiotic resistance is present Antibiotic-resistant organisms are more commonly associated with inappropriate therapy 40 Inappropriate treatment (%) Pseudomonas aeruginosa Kollef MH. Clin Infect Dis. 2000;3:S S. aureus Acinetobacter Other Klebsiella spp. pneumoniae
9 The Association between Antibiotic Use and Resistance Decreasing susceptibility trends over time were not statistically associated with the primary drug (e.g., organism susceptibility rate to imipenem with imipenem usage). However, secondary drug use was associated with susceptibility rates (e.g., susceptibility of E. cloacae to cefepime with piperacillin/tazobactam usage). Conclusions: These results suggest that antibiotic use - resistance relationships are influenced by the use of secondary antibiotics. Thus, a resistance problem may not be adequately addressed by simply altering the utilization of the primary antibiotic. Bosso et al. Joint meeting ICAAC/IDSA 2008 Getting it Right Upfront and Finishing Strong: De-escalation escalation & Short Courses Early, broad-spectrum empiric therapy Select antimicrobial based on local antibiogram Optimize antimicrobial exposures (i.e., make use of pharmacodynamic dosing strategies) Ensures early & maximally effective therapy To maintain efficacy and decrease risk of resistance Consider patient status & culture results early in therapy CHANGE (de-escalate) or STOP antibiotics as appropriate Employ short course therapy when possible Costs saved by avoiding treatment failure greater than costs spent on antimicrobial therapy 1. Niederman MS. Semin Respir Crit Care Med. 2006:27: Nicolau DP. Critical Care 2008;12:S1-5.
10 Outcomes of Bacteremia Due to P. aeruginosa Based on the Susceptibility of Piperacillin/Tazobactam 30-Day Mortality Rate (%) Pip/Tazo Control MIC, 32 or 64 mg/l MIC, 16 mg/l All = Susceptible Tam VH, et al. Clin Infect Dis. 2008;46: Nicolau Stewardship: Supplemental Strategies (I) Education is essential for any program Guidelines and clinical pathways can improve antimicrobial utilization Antimicrobial cycling insufficient data to recommend routine use Antimicrobial order forms can be an effective component of stewardship Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis. 2007;44:
11 Economics of the VAP Pathway Variable Control (n=73) Pathway (n=93) P-value LOTVAP 27.1± ±8.1 <0.001 LOS 35.0± ± * COSTVAP $75K $35K <0.001 COST after $95K $76K 0.077* Antibiotic Cost $934±1533 $766± Hospital costs similar for pathway ($24,501) and control ($28,13,817) over first week of VAP, but significantly lower for clinical pathway during week 2 ($12,231 vs $20,947, P<0.001). * Treatment on Clinical Pathway was independently associated with lower total LOS after VAP (P=0.012) and lower total hospital costs after VAP (P=0.033) in multivariable models. LOTVAP = length of VAP treatment; LOS = total length of hospital stay after identification of VAP; COSTVAP = hospital costs (2007$) of treating VAP; COST after = total hospital costs s (2007$) of treating VAP after VAP identification; Antibiotic Cost = acquisition cost of antibiotics used to treat VAP Nicasio AM, et al. Pharmacotherapy 2010; in press. Nicolau Stewardship: Supplemental Strategies (II) Combination therapy insufficient data to recommend routine use...to prevent resistance Streamlining or de-escalation can decrease antimicrobial exposure and save costs Dose optimization an important part of stewardship IV-to-PO switch can decrease LOS and health care costs LOS = Length of stay Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis. 2007;44:
12 Optimizing β-lactam Therapy: Maximizing Percent T>MIC Increased duration of infusion Prolonged infusion Same dose and dosing interval, ml, however, change duration of infusion (0.5 hr 3-4hr) Concentration (mg/l) MIC Time Since Start of Infusion (h) Nicolau What is Collateral Damage? A Movie? Resistant fecal flora? C. difficile infection? Resistant isolates? Gram positive? Gram negative? Industry spin? Whatever you want it to be?
13 Potential collateral damage from use of cephalosporins and quinolones Class of agent, pathogen(s) ) selected for: Third generation cephalosporins VRE ESBL Klebsiella sp. C difficile Quinolones MRSA Quinolone-resistant GNRs,, including P. aeruginosa DL Patterson Clin Infect Dis 2004; 38 (Suppl 4): S 341 ASP Management of S. aureus Bacteremia Using a Rapid PCR Test* Suspect SA Blood cultures drawn Start Vancomycin Growth in blood culture Gram stain: gm+cocci groups Results called to MD or RN Pre Xpert SA/MRSA BC Post Xpert SA/MRSA BC Suspect SA Blood cultures drawn Start Vancomycin Growth in blood culture Gram stain: gm+cocci groups Xpert SA/MRSA done in 1 hour Results called to MD or RN and PharmD Vanco continued Final report 2-4 days Vanco usually continued ID PharmD calls MD with antibiotic recommendation MSSA: Vanco switched to nafcillin or cefazolin MRSA: Vanco continued or switched to dapto * Real-time PCR rapid detection of MRSA/SA BC; GeneXpert MRSA/SA BC Bauer K, Goff D, et al. Clin Inf Dis 2010; 51:1074
14 Economic Impact of rapid PCR for SAB LOS decreased 6.2 Days mean days LOS 15.3 US dollars Mean Hospital costs decreased $21,287 (P=0.02) ICU costs decreased $9,930 (P=0.03) pre post pre-pcr post-pcr The TWO Carbapenem Formulary Reduces selective pressure on P. aeruginosa: : Effect of Ertapenem Basic Science Livermore, J Antimicrob Chemother. 2005;55: Collateral Damage OASIS 1 and OASIS 2, Eur J Clin Micro Infect Dis. 2005;24: STITCH, Surg Infect. 2007;8: Clinical Studies Crank, 44th IDSA Annual meeting, Toronto, Abstract 285. Goff, J Infection. 2008;57: Goldstein, AAC. 2009;53: Carmeli,, 47th ICAAC, Chicago, K-396K Eagye KJ, & Nicolau DP ICHE :485 ICHE May Conclusions Use of ertapenem did not decrease susceptibilities of Pseudomonas aeruginosa to carbapenems.
15 Anti-Pseudomal Carbapenem Stewardship (LA Hospital X/Y) Carbapenem Ertapenem Doripenem Imipenem Meropenem Cost per Dose $51-$54 $18-$27 (500 mg) $13-$14 (500 mg) $14 (1 gm) Cost per Day $51-$54 $54-$71 $39/42-$52/56 $42 Univariate ARIMA Model Fitted to the Usage Series Mont h Susceptibility P. aeruginosa Imipenem (%) Min Max Mean Median Standard Error Before Ertapenem added After Ertapenem was added, Before the substitution After the substitution Goldstein EJ, et al. Antimicrob Agents Chemother ;53:
16 25 OASIS II Therapy Resistant Enterobacteriaceae Subanalysis Ertapenem Ceftriaxone/Metronidazole Percent n= Resistant ESBL Producers Resistant ESBL Producers 2.1 Baseline End of Therapy 2 Weeks Post Therapy Adapted from DiNubile MJ, et al. Eur J Clin Microbiol Infect Dis 2005;24: Current Pathogenesis Model for C. difficile Infection (CDI) C. difficile acquisition Antimicrobial(s) C. difficile acquisition Asymptomati c C. difficile colonization Hospitalization CDI Acquisition of a toxigenic strain of C. difficile and failure to mount an anamnestic Toxin A IgG antibody response results in CDI. Courtesy of Dale Gerding, MD
17 Vanco vs OPT-80 Acquisition of VRE colonization during CDI treatment Percent T Louie et al AAC 2009 Vancomycin Fidaxomicin 41/133 8/115 P <0.001 Clostridium difficile Diagnostic Testing (LA Hospital Y) Test Cost/Test #Test/Month Cost EIA $3 70 $210 QC Test $3 50 $180 Average 2 test/patient/week 50 $300 Added QC 50 $180 Total LAMP Assay No QC $28 50 $480 or $9.60 per patient $1395 Change Policy for frequency of testing due to high sensitivity no duplicate tests
18 Difference between EIA & LAMP for Detection of C.difficile Difference $915/month or $10,980/year Less empirical drug use Better diagnostics Less isolation costs More specific therapy Equivalent cost but better quality of care CANDIDA (blood culture) Identification and Therapy
19 Yeast Traffic Light PNA FISH PN1870A Fluconzaole vs Echinocandin Agent Cost/day Days of Rx Total Cost 70% Fluconazole $5 10 $6,510 30% Echinocandin $76 10 $41,268 If no rapid ID - empirical Echinocandin for all for ~ 5 days, adds an extra $42,221 to costs Cost of FISH test ~$60 x 186 = $11,160 Cost savings, but it is also a quality of care issue
20 ASP in a Community Hospital Focused on 3 items IV to Oral ( low-hanging fruit ) Pre-op prophylaxis Selected drugs ID consult after 48 hours Antimicrobial cost per patient-day $14 $12 $10 $8 $6 $4 $2 $ Cost/Census Day Cost Savings for 2001 = $399,238 Cost Savings for 2002 = $659,812 Cost Savings for 2003 = $782,153 Total Cost Savings = $1,841,203 Philmon C, et al. Infect Control Hosp Epidemiol. 2006;27: Abx Stewardship Strategies 522/1044 (50%) ID respondents Strategy Current ASP Planned ASP Primary 264 (100%) 41 (100%) Single 63 (24%) 14 (34%) Formulary restriction 17 (6%) 8 (19%) Preauthorization 5 (2%) 0 PostRx review-feedback 41 (16%) 6 (15%) Combinations 194 (73%) 23 (56%) Restriction & Pre-auth 57 (22%) 3 (7%) Restriction & Post RX 33 (12%) 8 (19%) All three 83 (31%) 12 (29%) No Primary Strategy 8 (3%) 4 (10%) Johannsson et al ICHE 2011; 32:367
21 Abx Stewardship Supplemental Strategies None 11 (4%) Education 212 (80%) Guidelines/Pathways 187 (71%) IV po conversion 161 (61%) Dose optimization 147 (55%) De-escalation/Streamlining 132 (50%) Automatic Stop orders 110 (42%) Abx order forms 75 (28%) Cycling 6 (2%) Johannsson et al ICHE 2011; 32:377 ASP Criteria for Abx Review High Cost 215 (87%) Potential misuse 166 (67%) Broad spectrum 141 (57%) Potential IV po 130 (52%) Resistance profile(eg MRSA) 130 (52%) Novel agents 128 (52%) High Use agents 114 (46%) High Adverse Rxn 98 (40%) Overlapping spectrum 70 (28%) Site of infection (eg Blood) 44 (18%) Johannsson et al ICHE 2011: 32:367
22 Outcomes data useful to support ASP Johannsson et al ICHE :367 Administration Views Be Prepared Who is the decision maker? CEO, COO, other Who is the best proponent Track record Educate the decision maker Not too much detail on 1 st meeting- set the stage ROI Quality and Economic Aspects Have a Timeline Identify who needs to get the message
23 Administration Views Undersell and Over deliver Be committed to the Program Prioritize existing resources Don t join BMW club Bitch, moan and whine Identify who is doing it already- success and value Legislation & Regulation Do it for the right reason Thank you
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Background Why Antimicrobial Stewardship 30-50% of antibiotic use in hospitals are unnecessary or inappropriate Appropriate antimicrobial use is a medication-safety and patient-safety
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationAntibiotic Stewardship in the Hospital Setting
Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship
More informationHealthcare Facilities and Healthcare Professionals. Public
Document Title: DOH Guidelines for Antimicrobial Stewardship Programs Document Ref. Number: DOH/ASP/GL/1.0 Version: 1.0 Approval Date: 13/12/2017 Effective Date: 14/12/2017 Document Owner: Applies to:
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationOverview of Antimicrobial Stewardship
Overview of Antimicrobial Stewardship Kurt B. Stevenson, MD, MPH Professor of Medicine and Epidemiology Colleges of Medicine and Public Health Medical Director, Antimicrobial Stewardship Program The Ohio
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationAntimicrobial stewardship
Antimicrobial stewardship Magali Dodemont, Pharm. with the support of Wallonie-Bruxelles International WHY IMPLEMENT ANTIMICROBIAL STEWARDSHIP IN HOSPITALS? Optimization of antimicrobial use To limit the
More informationThe Rise of Antibiotic Resistance: Is It Too Late?
The Rise of Antibiotic Resistance: Is It Too Late? Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine None DISCLOSURES THE PROBLEM Antibiotic resistance is one of the
More informationTherapeutic Strategies for Gram Negative Multi- Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical Center
Therapeutic Strategies for Gram Negative Multi- Bacterial Infections Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical Center Columbus,
More informationAntimicrobial Stewardship 101
Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More informationIt s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings. Emily Heil, PharmD, BCPS-AQ ID, AAHIVP
It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings Emily Heil, PharmD, BCPS-AQ ID, AAHIVP Conflict of Interest I have no conflicts of interest to disclose related to the content
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationBest Practices: Goals of Antimicrobial Stewardship
Best Practices: Goals of Antimicrobial Stewardship Gail Scully, M.D, M.P.H. and Elizabeth Radigan, PharmD, BCPS UMass Memorial Medical Center Division of Infectious Disease Department of Medicine September
More informationANTIBIOTIC STEWARDSHIP
ANTIBIOTIC STEWARDSHIP S.A. Dehghan Manshadi M.D. Assistant Professor of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences Issues associated with use of antibiotics were recognized
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationDisclosures ANTIMICROBIAL STEWARDSHIP. Objectives. What is Antimicrobial Stewardship? Who is talking about it? Why Stewardship 9/28/12
Disclosures ANTIMICROBIAL STEWARDSHIP Nothing to disclose. I may inadvertently mention proprietary products, but it is not meant as an endorsement. Katherine Lusardi, PharmD Clinical Specialist, Antimicrobial
More informationMDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC
MDRO s, Stewardship and Beyond Linda R. Greene RN, MPS, CIC linda_greene@urmc.rochester.edu Evolving Threat of Antimicrobial Resistance Why are MDROs important? Limited treatment options Associated with:
More informationWhy Antimicrobial Stewardship?
Antimicrobial Stewardship: Why and How CAPT Arjun Srinivasan, MD Associate Director for Healthcare Associated Infection Prevention Programs Division of Healthcare Quality Promotion Why Antimicrobial Stewardship?
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationAntimicrobial Stewardship-way forward. Dr. Sonal Saxena Professor Lady Hardinge Medical College New Delhi
Antimicrobial Stewardship-way forward Dr. Sonal Saxena Professor Lady Hardinge Medical College New Delhi Lets save what we have! What is Antibiotic stewardship? Optimal selection, dose and duration of
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters
More informationAntibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE
Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Crisis: Antibiotic Resistance Success Strategy WWW.optimistic-care.org
More informationAntibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationAntimicrobial Stewardship. October 2012
Antimicrobial Stewardship October 2012 Rising Antimicrobial Resistance Methicillin resistant staphylococcus aureus (MRSA) Vancomycin resistant enterococci (VRE) MDR and extremely drug resistant (XDR TB)
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationAntimicrobial Stewardship in the Hospital Setting
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor
More informationCommonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities
Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Introduction As the problem of antibiotic resistance continues to worsen in all healthcare setting, we
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationANTIBIOTIC STEWARDSHIP. Brian Mayhue, Pharm D, CGP Director of Pharmacy Palm Beach Gardens Medical Center
ANTIBIOTIC STEWARDSHIP Brian Mayhue, Pharm D, CGP Director of Pharmacy Palm Beach Gardens Medical Center Antibiotic Resistance It is not difficult to make microbes resistant to penicillin in the laboratory
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies
ASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies Theresa Jaso, PharmD, BCPS (AQ-ID) Network Clinical Pharmacy Specialist Infectious Diseases Seton Healthcare Family Ascension
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationGrey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report to 214 Table of Contents I. Introduction..
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationAntibiotic Stewardship for Hospital Acquired Infection Prevention
Antibiotic Stewardship for Hospital Acquired Infection Prevention Emi Minejima, PharmD Assistant Professor of Clinical Pharmacy USC School of Pharmacy minejima@usc.edu Objectives Review the elements of
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationBest Practices for Antimicrobial Stewardship Programs. October 25, :00 AM 5:00 PM New Orleans, LA Room:
Best Practices for Antimicrobial Stewardship Programs October 25, 2016 8:00 AM 5:00 PM New Orleans, LA Room: 288-290 Co-organized by The Society for Healthcare Epidemiology of America (SHEA) and Pediatric
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationGet Smart For Healthcare
Get Smart For Healthcare Know When Antibiotics Work Marry Bardin, Quality Improvement Advisor June 9, 2015 Why We Need to Improve In-patient Antibiotic Use Antibiotics are misused in hospitals Antibiotic
More informationAppropriate Antimicrobial Use in California: The Path of Least Resistance
Appropriate Antimicrobial Use in California: The Path of Least Resistance BEACON Fall Exchange November 9, 2011 Kavita K. Trivedi, MD Healthcare Associated Infections Program California Department of Public
More information10 Golden rules of Antibiotic Stewardship in ICU. Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017
10 Golden rules of Antibiotic Stewardship in ICU Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017 10 golden rules of Antibiotic Stewardship in the ICU ID, Pharma & Micro advice
More informationAddressing ABX Resistance
Antimicrobial Stewardship: When to Study, and When to Act Addressing ABX Resistance Curtailing ABX Resistance Antimicrobial Use Interventions Agricultural Animals Humans Infection Control Interventions
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationAntimicrobial Stewardship Strategy: Formulary restriction
Antimicrobial Stewardship Strategy: Formulary restriction Restricted dispensing of targeted antimicrobials on the hospital s formulary, according to approved criteria. The use of restricted antimicrobials
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationPromoting Appropriate Antimicrobial Prescribing in Secondary Care
Promoting Appropriate Antimicrobial Prescribing in Secondary Care Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2015 Introduction Background ESPAUR
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationLUNCH AND LEARN. January 13, CE Activity Information & Accreditation
LUNCH AND LEARN Overview of Antimicrobial Stewardship January 13, 2017 Featured Speaker: Jamie Kisgen, PharmD, BCPS (AQ ID) Pharmacotherapy Specialist Infectious Diseases Antimicrobial Stewardship Program
More information1. List three activities pharmacists can implement to support. 2. Identify potential barriers to implementing antimicrobial
OPTIMIZING ANTIMICROBIAL STEWARDSHIP: IT STARTS IN THE EMERGENCY DEPARTMENT! 1 2 Objectives 1. List three activities pharmacists can implement to support health-system antimicrobial stewardship programs
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationUpdates in Antimicrobial Stewardship
Updates in Antimicrobial Stewardship Andrew Hunter, Pharm.D., BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center andrew.hunter@va.gov Disclosures No disclosures
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationAntimicrobial Stewardship Strategy:
Antimicrobial Stewardship Strategy: Prospective audit with intervention and feedback Formal assessment of antimicrobial therapy by trained individuals, who make recommendations to the prescribing service
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationAntimicrobial Stewardship Esperienza Torinese
Pisa 15 Novembre 2016 Antimicrobial Stewardship Esperienza Torinese Francesco G. De Rosa Dipartimento di Scienze Mediche Università di Torino Antimicrobial Stewardship First introduced by Dale Gerding
More informationImpact of Antimicrobial Stewardship Program
Impact of Antimicrobial Stewardship Program Ripal Joshi, Pharm.D. AAHIVP Tampa General Hospital January 28, 2016 Objectives Provide an overview on antimicrobial stewardship programs (ASP) Describe the
More information6/15/2017 PART 1: THE PROBLEM. Objectives. What is Antimicrobial Resistance? Conflicts of Interest Disclosure Statement
Conflicts of Interest Disclosure Statement Getting a grasp on Antibiotic Use and Resistance: Principles of Antimicrobial Stewardship Speaker has nothing to disclose. Jacob M Kesner, PharmD UNMH PGY-2 Infectious
More informationAntimicrobial Stewardship Advisory Committee Meeting
Antimicrobial Stewardship Advisory Committee Meeting August 25, 2016 3:00 PM-4:30 PM Washington State Dept of Health Room A42 1610 NE 150th St Shoreline, WA 98155 Call in: (571) 317-3116 Access Code: 211-449-029
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report
Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 216 Table of Contents I. Introduction... 3 II. Executive Summary... 5 III. MCH Antimicrobial Utilization Reports...
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationPreventing and Responding to Antibiotic Resistant Infections in New Hampshire
Preventing and Responding to Antibiotic Resistant Infections in New Hampshire Benjamin P. Chan, MD, MPH NH Dept. of Health & Human Services Division of Public Health Services May 23, 2017 To bring a greater
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationMHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative
MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative Place picture here Nov. 14, 2017 Reminders For best sound quality, dial in at 1-800-791-2345 and enter code 11076 Please use the chat box to ask questions!
More informationANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES
ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP COLLABORATIVE COLORADO HOSPITAL ASSOCIATION MARCH 23, 2016 Bridget Olson, RPh Infectious Disease Pharmacist, Sharp Coronado
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationOverview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases
Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.
More informationAntimicrobial Stewardship Basics Why, What, Who, and How
Antimicrobial Stewardship Basics Why, What, Who, and How Philip Chung, PharmD, MS, BCPS ASAP Community Network Pharmacy Coordinator September 19, 2017 Objectives List reasons for developing antimicrobial
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationAntimicrobial Stewardship Program
Antimicrobial Stewardship Program David R. Woodard, MSc, FSHEA, CIC CDC: Antibiotic Resistance Threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ CDC Threat Levels
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationPotential Conflicts of Interest. Schematic. Reporting AST. Clinically-Oriented AST Reporting & Antimicrobial Stewardship
Potential Conflicts of Interest Clinically-Oriented AST Reporting & Antimicrobial Stewardship Hsu Li Yang 27 th September 2013 Research Funding: Pfizer Singapore AstraZeneca Janssen-Cilag Merck, Sharpe
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationAntimicrobial Stewardship Strategy: Intravenous to oral conversion
Antimicrobial Stewardship Strategy: Intravenous to oral conversion Promoting the use of oral antimicrobial agents instead of intravenous administration when clinically indicated. Description This is an
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationHospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationAntimicrobial Stewardship: The Premier Health Experience
Antimicrobial Stewardship: The Premier Health Experience Steve Burdette, MD, FIDSA Professor of Medicine Wright State University Boonshoft School of Medicine Director of Antimicrobial Stewardship Miami
More informationAntibiotic Stewardship: The Facility Role and Implementation. Tim Cozad, LPN, Lead LTC Health Facilities Surveyor
Antibiotic Stewardship: The Facility Role and Implementation Tim Cozad, LPN, Lead LTC Health Facilities Surveyor Phase II CMS Regulatory Changes Current information available includes: New Survey Process
More informationLinda Taggart MD FRCPC Infectious Diseases Physician Lead Physician, Antimicrobial Stewardship Program St. Michael s Hospital
Linda Taggart MD FRCPC Infectious Diseases Physician Lead Physician, Antimicrobial Stewardship Program St. Michael s Hospital no industry conflicts of interest salary support to lead Antimicrobial Stewardship
More informationHot Topics in Antimicrobial Stewardship. Meghan Brett, MD Medical Director, Antimicrobial Stewardship University of New Mexico Hospital
Hot Topics in Antimicrobial Stewardship Meghan Brett, MD Medical Director, Antimicrobial Stewardship University of New Mexico Hospital Antimicrobial Stewardship Goals Primary Goal Optimize clinical outcomes
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report
Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report January June 215 Table of Contents I. Introduction... 3 II. CHASC Antimicrobial Utilization Reports... 4 III. Executive Summary...
More informationHorizontal vs Vertical Infection Control Strategies
GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,
More information2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea
2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea Submitted by: Asia Pacific Foundation for Infectious Diseases Policy Forum on Strengthening Surveillance and Laboratory Capacity to
More information